Position on key issues
In our focus to help patients with serious diseases, we have developed clear positions on important policies and topics related to healthcare, regulatory, intellectual property and pricing. Learn more about our positions below.
Climate change position
BMS believes that the health of people is inextricably linked to the health of the planet, and we remain committed to improving environmental health in all the places we live, work and sell our products today.
Clinical trial communication commitment
Clinical trial diversity position
Clinical trials are an integral step in the development of new, potentially life-saving drugs and therapies.
Counterfeit drugs position
Drug shortages position
BMS is committed to minimizing the impact of drug shortages on patients and supports ongoing and balanced discussions with regulatory authorities and policymakers to address both anticipated and unanticipated drug shortfalls.
Early patient access to investigational medicines
ESG governance and operating model
Sound Environmental, Social and Governance (ESG) management practices and oversight are considered to be a strategic component of businesses that are successful over the long term, helping enhance shareholder value as well as delivering benefits to all of our stakeholders. Read more about our ESG governance and operating model.
How we price our medicines
Global position statement on human rights
Bristol Myers Squibb (BMS) is committed to respecting human rights throughout our own business and our value chain.
Intellectual property (IP) position
Intellectual property (IP) encourages and protects innovation, promoting future research and development (R&D) of innovative medicines for patients with unmet needs.
Interactions with healthcare providers - Sunshine Act (US)
Pandemic preparedness position
At BMS, we aim to contribute to a world that is better prepared to prevent and respond to pandemics, minimizing loss of life and livelihoods for communities globally.
Pharmaceuticals in the environment position
Bristol Myers Squibb is committed to protecting the health and safety of our employees, contractors, customers, the public and the environment by conducting business in an environmentally responsible and sustainable manner.
PhRMA's code on interactions with healthcare professionals
PhRMA's guiding principles on direct-to-consumer advertisements
Policy and advocacy engagement and political contributions
Strengthening health systems position
BMS believes we need strong and resilient healthcare systems globally. We strive to contribute in meaningful ways to enable holistic solutions that address systemic challenges and root causes hindering access.
Support for European patient organizations
As part of our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, Bristol Myers Squibb and the Bristol Myers Squibb Foundation support patient organizations across Europe through partnerships, grants and charitable contributions.
Tax is a critical element of Bristol Myers Squibb (BMS) corporate responsibility and part of our commitment to ensure that we are operating in a way that is ethical and responsible.
Many stakeholders, including policymakers and non-governmental organizations, have shown an increased interest in the disclosure of information related to medicines across a variety of domains.
Value assessments position
Value assessments (VAs) refer to the different approaches used to assess value, including Health Technology Assessments (HTAs) and other value frameworks, that measure the magnitude of clinical benefit (sometimes in relation to costs).